Clinical Validation of Plasma p‐217tau in Neurological Diseases
ALS and iNPH are two major pitfalls for the clinical application of plasma p-217tau as a biomarker of AD. Lower motor neuron injury in ALS and cognitive dysfunction in iNPH were both found to be associated with elevated plasma p-217tau levels.
Authors
- Kunihiko Ishizawa (ORCID: https://orcid.org/0000-0002-1753-3626)
- Takumi Nakamura (ORCID: https://orcid.org/0000-0001-5125-8579)
- Masakuni Amari
- Takashi Sugawara (ORCID: https://orcid.org/0000-0003-4621-8710)
- Masamitsu Takatama
- Seiji Kinoshita
- Ryoma Takahashi
- Hiroo Kasahara
- Mikio Shoji
- Yoshio Ikeda
- Chikage Uchida
- Tetsuya Ueda
- Takeshi Kawarabayashi
- Kentaro Hashimoto
Institutions
- Hirosaki University (JP)
- Maebashi Institute of Technology (JP)
- Gunma University (JP)
- Sumco Corporation (Japan) (JP)
Publication Details
- Journal
- Annals of Clinical and Translational Neurology
- Published
- 2026-03-09
- DOI
- https://doi.org/10.1002/acn3.70359
- Primary Topic
- Amyotrophic Lateral Sclerosis Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00